• Buheruk V. Odessa National Medical University, Odessa, Ukraine
  • Voloshyna O. Odessa National Medical University, Odessa, Ukraine
  • Dukova O. Odessa National Medical University, Odessa, Ukraine
  • Lysij I. Odessa National Medical University, Odessa, Ukraine
  • Naydionova E. Odessa National Medical University, Odessa, Ukraine
  • Dichko T. Odessa National Medical University, Odessa, Ukraine



statins, new-onset diabetes mellitus


Aim. Current review summarized and analysed existing evidence of diabetogenic effect of statins and potential ways to overcome this problem in non-diabetic and diabetic patients. Materials and methods. Systematic literature review included results of experimental and clinical studies, multi-center placebo-controlled trials (JUPITER, ТNТ, IDEAL, SPARCL, METSIM, WOSCOPS, ALLHAT-LLT, PROSPER, etc.), systematic reviews and meta-analyses, current guidelines on statin prescription in high-risk patients and non-diabetic patients.Results of the reviewed clinical trials assessing the effects of long-term statin administration, data from randomized clinical trials and genetic studies provide convincing evidence of small, yet significant increase in absolute risk of new-onset diabetes (1 case of diabetes per 1000 patients per 1 year of treatment), concurrently preventing 5 new cases of cardiovascular disease. Diabetogenic properties are identified as probable class-effect of statins, with risk increased in high-intensity statin therapy. Diabetogenic effects are mediated through reduction in pancreatic β-cell function and impaired insulin resistance. Based on current international guidelines (ESC 2019, ADA 2020), the article highlights that despite modest diabetogenic potential, statins are recommended for primary and secondary prevention in patients with high risk of cardiovascular complications, including patients with diabetes. Conclusions. Statin therapy, especially high-intensity dosing can promote new cases of diabetes, particularly in patients with pre-existing metabolic syndrome and insulin resistance. Despite moderate diabetogenic effect statins are routinely recommended (ESC 2019, ADA 2020) for primary and secondary prevention in patients at high risk of cardiovascular complications, including diabetic patients. Statin therapy should be tailored to patient’s age, sex, concomitant diseases, parameters of lipid and glucose metabolism and presence of additional diabetogenic risk factors. Patients require lifestyle modification to reduce the risk of diabetes.


Barquera S, Pedroza-Tobнas A, Medina C, et al. Arch Med Res 2015; 46(5): 328-338. doi:

Cosentino F, Grant P, Aboyans V. et al. Eur Heart J 2019; 41(2): 255-323. doi:

Mach F, Baigent C, Catapano A, et al. Eur Heart J 2019.doi:

Thakker D, Nair S, Pagada A, et al. Pharmacoepidemiol Drug Saf 2016; 25: 1131-1149.

Armitage J. Lancet 2007;370: 1781-1790.

Agarwala A, Kulkarni S, Maddox T. Curr Cardiol Rep 2018; 20: 50. doi:

Angelidi AM, Stambolliu E, Adamapoulou KI, et al. Int J Endocrinol 2018; 2018: 8380192. doi:

Cai R, Yuan Y, Yi Z, et al. PloS One 2014; 9(8): e104922.

Ridker P, Danielson E, Fonseca F, et al. N Engl J Med 2008; 359: 2195-2207.

Koh KK, Quon MJ, Sakuma I. Int J Cardiol 2013; 166(2): 509-515.

National Institutes of Health. Search the Liver Tox Database. LIVERTOX, available at:

Waters D, Ho J, DeMicco D, et al. J Am Coll Cardiol 2011; 57: 1535-1545.

Waters D, Ho J, Boekholdt S, et al. J Am Coll Cardiol 2013; 61: 148-152.

Go AS, Ambrosy AP, Kheder K, Fan D. Am J Cardiol 2019: S0002-9149(19)31305-0. doi:

Cederberg H, Stančáková A, Yaluri N, et al. Diabetologia 2015; 58: 1109-1117.

Ahmadizar F, Ochoa-Rosales C, Glisic M, et al. Br J Clin Pharmacol 2019; 85: 993-1002.

Preiss D, Seshasai S, Welsh P, Murphy S, et al. JAMA 2011; 305: 2556-2564.

Shepherd J, Cobbe S, Ford I, et al. N Engl J Med 1995;333: 1301-1307.

Officers A. JAMA 2002; 288: 2998-3007.

Shepherd J, Blauw G, Murphy M, et al. Lancet 2002;360: 1623-1630.

Teramoto T, Shimano H, Yokote K, Urashima M. Expert Opin Pharmacother 2010; 11: 817-828.

Newman CB, Preiss D, Tobert JA, et al. Arteriosclerosis,Thrombosis and Vascular Biology 2019; 39: e38-e81.


Carmena R, Betteridge DJ. Cur Atheroscler Rep 2019;21: 23. doi:

Betteridge DJ, Carmena R. Nat Rev Endocrinol 2016;12: 90-110.

Swerdlow D, Preiss D, Kuchenbaecker K, et al.Lancet 2015; 385(9965): 351-361. doi:

Chan DC, Pang J, Watts GF. Curr Atheroscler Rep 2015;17(1): 472. doi: 1007/s11883-014-0472-72015.

Yada T, Nakata M, Shiraishi T, Kakei M. Br J Pharmacol 1999; 126: 1205-1213.

Mach F, Ray KK, Wiklund O, et al. Eur Heart J 2018;39(27): 2526-2539. doi:

Nakata M, Nagasaka S, Kusaka I, et al. Diabetologia 2006; 49: 1881-1892.

Jiang Z, Yu B, Li Y. Med Sci Monit 2016; 22: 2825-2830.

Parpal S, Karlsson M, Thorn H, Stralfors P. J Biol Chem 2001; 276: 9670-9678.

Larsen S, Stride N, Hey-Mogensen M, et al. J Am Coll Cardiol 2013; 61: 44-53.

Lorza-Gil E, Salerno AG, Wanschel AC, et al. Toxicology 2016; 344-346: 42-52.

Frayling T.M. Lancet 2015; 385: 310-312.

Li S, Shin HJ, Ding EL, et al. JAMA 2009; 302: 179-188.

Baker WL, Talati R, White CM, et al. Diabetes Res Clin Pract 2010; 87: 98-107.

Metz S, Rabaglia M, Stock J, Kowluru A. Biochem 1993;295: 31-40.

Yaluri N, Modi S, Lуpez Rodrнguez M, et al. PloS One 2015; 10: e0142902.

ADA. Cardiovascular Disease and Risk Management:Standards of Medical Care in Diabetes – 2020. Diabetes Care 2020; 43(1): S111-134. doi:

Kamran H, Kupferstein E, Sharma N, et al. Cardiorenal Med 2018; 8(2): 105-112. doi:




How to Cite

Buheruk, V., Voloshyna, O., Dukova, O., Lysij, I., Naydionova, E., & Dichko, T. (2021). THE PROBLEM OF STATINS DIABETOGENIC POTENTIAL AND WAYS OF ITS SOLUTION (review). Problems of Endocrine Pathology, 74(4), 147-154.